journal article·2024-12Open access

Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement

Nazareth Milagros Carigga Gutierrez, Tristan Le Clainche, Anne‐Laure Bulin, Sofia Leo, Malika Kadri, Ahmed Gamal Ali Abdelhamid, Núria Pujol‐Solé, Girgis Obaid, Marc‐André Hograindleur, Vincent Gardette, Benoit Busser, Vincent Motto‐Ros, Véronique Josserand, Maxime Henry, Lucie Sancey, Amandine Hurbin, Hélène Elleaume, Eaazhisai Kandiah, Xavier Le Guével, Jean‐Luc Coll, Mans Broekgaarden

Advanced Materials· Volume 36· Issue 50

Abstract

Abstract Chemoradiation therapy is on the forefront of pancreatic cancer care, and there is a continued effort to improve its safety and efficacy. Liposomes are widely used to improve chemotherapy safety, and may accurately deliver high‐Z element‐ radiocatalytic nanomaterials to cancer tissues. In this study, the interaction between X‐rays and long‐circulating nanoliposome formulations loaded with gold nanoclusters is explored in the context of oxaliplatin chemotherapy for desmoplastic pancreatic cancer. Hydrophobic gold nanoclusters stabilized with dodecanethiol (AuDDT) are efficiently incorporated in nanoliposomal bilayers. AuDDT‐nanoliposomes significantly augmented radiation‐induced • OH production, which is most effective with monochromatic X‐rays at energies that exceed the K‐shell electron binding energy of Au (81.7 keV). Cargo release assays reveal that AuDDT‐nanoliposomes can permeabilize lipid bilayers in an X‐ray dose‐ and formulation‐dependent manner. The radiocatalytic effect of AuDDT‐nanoliposomes significantly augments radiotherapy and oxaliplatin‐chemoradiotherapy outcomes in 3D pancreatic microtumors. The PEGylated AuDDT‐nanoliposomes display high tumor accumulation in an orthotopic mouse model of pancreatic cancer, showing promise for nanoliposomes as carriers for radiocatalytic nanomaterials. Altogether, compelling proof for chemo‐radiation dose‐enhancement using AuDDT‐nanoliposomes is presented. Further improving the nanoliposomal loading of high‐Z elements will advance the safety, efficacy, and translatability of such chemoradiation dose‐enhancement approaches.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanocluster Synthesis and Applications · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Université Grenoble‐Alpes Inserm U1209 CNRS UMR 5309 Institute for Advanced Biosciences Allée des Alpes La Tronche 38700 France

Porphychem SAS Longvic 21600 France

Department of Bioengineering University of Texas at Dallas Richardson TX 75080 USA

European Synchrotron Radiation Facility CM01 Beamline 71 Avenue des Martyrs Grenoble 38000 France

Université Lyon 1 Institut Lumière Matière, CNRS UMR 5306 Université de Lyon Villeurbanne France

University Hospital of Grenoble Alpes Grenoble 38000 France

Université de Grenoble‐Alpes Synchrotron Radiation for Biomedicine, Inserm UA07 2280 Rue de la Piscine Saint Martin d'Hères 38400 France

Funding

HORIZON EUROPE European Research Council · Phospholipid Research Center · Institut National de la Santé et de la Recherche Médicale

References (100+)

Show source-provided references
1. 10.1038/s41571-021-00501-410.1038/s41571-021-00501-4 ↗
2. 10.1038/s41572-020-00224-310.1038/s41572-020-00224-3 ↗
3. 10.1038/nrclinonc.2018.910.1038/nrclinonc.2018.9 ↗
4. 10.1002/cncr.3085610.1002/cncr.30856 ↗
5. 10.1245/s10434-014-4274-510.1245/s10434-014-4274-5 ↗
6. 10.1002/jso.2523310.1002/jso.25233 ↗
7. 10.1097/COC.000000000000019310.1097/COC.0000000000000193 ↗
8. 10.1038/s41571-021-00546-510.1038/s41571-021-00546-5 ↗
9. 10.1038/s41575-020-0300-110.1038/s41575-020-0300-1 ↗
10. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
11. 10.1038/nrclinonc.2016.11910.1038/nrclinonc.2016.119 ↗
12. 10.1038/nrc395810.1038/nrc3958 ↗
13. 10.1158/0008-5472.CAN-17-170010.1158/0008-5472.CAN-17-1700 ↗
14. 10.1002/advs.20210459410.1002/advs.202104594 ↗
15. 10.1021/acs.molpharmaceut.8b0005210.1021/acs.molpharmaceut.8b00052 ↗
16. 10.1016/j.jconrel.2019.01.03010.1016/j.jconrel.2019.01.030 ↗
17. 10.1007/s10555-015-9588-710.1007/s10555-015-9588-7 ↗
18. 10.1007/s10555-022-10064-010.1007/s10555-022-10064-0 ↗
19. Snyder J. W. · Cancer Res. · 2003 · 63 · 8126
20. 10.1016/j.jconrel.2014.12.03810.1016/j.jconrel.2014.12.038 ↗
21. 10.1021/acs.nanolett.9b0085910.1021/acs.nanolett.9b00859 ↗
22. 10.1038/nnano.2015.31110.1038/nnano.2015.311 ↗
23. 10.1111/php.1321910.1111/php.13219 ↗
24. 10.1016/j.radonc.2015.04.02110.1016/j.radonc.2015.04.021 ↗
25. 10.1016/j.radphyschem.2016.07.00710.1016/j.radphyschem.2016.07.007 ↗
26. X‐Ray Mass Attenuation Coefficients NISThttps://www.nist.gov/pml/x‐ray‐mass‐attenuation‐coefficients(accessed: July 2021).
27. 10.1016/j.nano.2011.01.01410.1016/j.nano.2011.01.014 ↗
28. 10.1021/jp075253u10.1021/jp075253u ↗
29. 10.1088/0031-9155/49/18/N0310.1088/0031-9155/49/18/N03 ↗
30. 10.1039/D0NR01138J10.1039/D0NR01138J ↗
31. 10.1016/j.biomaterials.2017.08.01710.1016/j.biomaterials.2017.08.017 ↗
32. 10.1002/smll.20190096810.1002/smll.201900968 ↗
33. 10.1002/adhm.20130018910.1002/adhm.201300189 ↗
34. 10.1039/C8NR05299A10.1039/C8NR05299A ↗
35. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
36. 10.1021/acs.chemrev.5b0070310.1021/acs.chemrev.5b00703 ↗
37. 10.1021/la302740j10.1021/la302740j ↗
38. 10.1021/nl102387n10.1021/nl102387n ↗
39. 10.1021/la302734r10.1021/la302734r ↗
40. 10.1021/acs.jpcb.7b0170210.1021/acs.jpcb.7b01702 ↗
41. 10.1039/C8NR02973C10.1039/C8NR02973C ↗
42. Apolline A. S. · ChemRxiv · 2023
43. 10.1021/acs.langmuir.8b0255310.1021/acs.langmuir.8b02553 ↗
44. 10.1021/nn204201610.1021/nn2042016 ↗
45. 10.1021/jp910374s10.1021/jp910374s ↗
46. 10.1002/smll.20090162310.1002/smll.200901623 ↗
47. 10.1016/0304-4157(79)90012-110.1016/0304-4157(79)90012-1 ↗
48. 10.1016/S0070-2161(08)60213-010.1016/S0070-2161(08)60213-0 ↗
49. 10.1039/b311191c10.1039/b311191c ↗
50. 10.1088/0953-8984/15/1/30410.1088/0953-8984/15/1/304 ↗
51. 10.1016/j.jconrel.2019.12.02310.1016/j.jconrel.2019.12.023 ↗
52. Auger Electron Spectroscopy Methodshttps://serc.carleton.edu/msu_nanotech/methods/aes.html(accessed: March 2024 ).
53. 10.1021/acscentsci.9b0112110.1021/acscentsci.9b01121 ↗
54. 10.1118/1.359264610.1118/1.3592646 ↗
55. Pogue B. W. · J. Biomed. Opt. · 2018 · 23
56. 10.1016/S0162-0134(00)80269-X10.1016/S0162-0134(00)80269-X ↗
57. 10.1038/srep0001810.1038/srep00018 ↗
58. 10.1016/0304-4157(92)90039-D10.1016/0304-4157(92)90039-D ↗
59. 10.1002/smll.20150396610.1002/smll.201503966 ↗
60. 10.1016/j.biomaterials.2019.11942110.1016/j.biomaterials.2019.119421 ↗
61. 10.18632/oncotarget.2678010.18632/oncotarget.26780 ↗
62. 10.1016/j.addr.2015.12.01210.1016/j.addr.2015.12.012 ↗
63. 10.1111/j.1751-1097.2009.00585.x10.1111/j.1751-1097.2009.00585.x ↗
64. 10.1007/s10103-008-0539-110.1007/s10103-008-0539-1 ↗
65. 10.1016/S0140-6736(23)01366-110.1016/S0140-6736(23)01366-1 ↗
66. 10.1016/j.semradonc.2023.10.00210.1016/j.semradonc.2023.10.002 ↗
67. 10.1016/j.freeradbiomed.2013.03.01910.1016/j.freeradbiomed.2013.03.019 ↗
68. 10.1007/s00280-011-1700-210.1007/s00280-011-1700-2 ↗
69. 10.1073/pnas.150160511210.1073/pnas.1501605112 ↗
70. 10.1016/j.canlet.2019.05.00510.1016/j.canlet.2019.05.005 ↗
71. 10.1002/smtd.20220057010.1002/smtd.202200570 ↗
72. 10.1667/RR0380.110.1667/RR0380.1 ↗
73. 10.1038/ncomms454610.1038/ncomms4546 ↗
74. 10.1158/0008-5472.CAN-15-039110.1158/0008-5472.CAN-15-0391 ↗
75. 10.1016/1011-1344(94)06998-010.1016/1011-1344(94)06998-0 ↗
76. 10.1111/php.1300210.1111/php.13002 ↗
77. 10.1016/0005-2760(92)90228-N10.1016/0005-2760(92)90228-N ↗
78. 10.1016/S0378-5173(02)00703-210.1016/S0378-5173(02)00703-2 ↗
79. 10.1016/0005-2736(91)90246-510.1016/0005-2736(91)90246-5 ↗
80. 10.3390/cancers1322565610.3390/cancers13225656 ↗
81. 10.1002/smsc.20230030710.1002/smsc.202300307 ↗
82. 10.1021/acs.analchem.2c0491010.1021/acs.analchem.2c04910 ↗
83. 10.1021/acsami.4c0244510.1021/acsami.4c02445 ↗
84. 10.1016/j.jconrel.2007.06.00910.1016/j.jconrel.2007.06.009 ↗
85. 10.1016/j.ejps.2017.05.00110.1016/j.ejps.2017.05.001 ↗
86. 10.3390/nano1221387510.3390/nano12213875 ↗
87. 10.1021/acs.jpclett.2c0107110.1021/acs.jpclett.2c01071 ↗
88. 10.1016/j.ijpharm.2022.12243910.1016/j.ijpharm.2022.122439 ↗
89. 10.1002/adfm.20200975010.1002/adfm.202009750 ↗
90. 10.1016/j.chemphyslip.2018.11.00710.1016/j.chemphyslip.2018.11.007 ↗
91. 10.1002/adom.20220147410.1002/adom.202201474 ↗
92. 10.1107/S205979831900688010.1107/S2059798319006880 ↗
93. 10.1038/nmeth.419310.1038/nmeth.4193 ↗
94. Burt A. · FEBS Open Bio · 2024
95. 10.1107/S002188980700285310.1107/S0021889807002853 ↗
96. 10.1016/S0168-9002(03)01368-810.1016/S0168-9002(03)01368-8 ↗
97. 10.1039/C4NR07444K10.1039/C4NR07444K ↗
98. 10.1002/advs.20200167510.1002/advs.202001675 ↗
99. 10.2174/0929867311320999021110.2174/09298673113209990211 ↗
100. 10.1038/s41598-017-16622-910.1038/s41598-017-16622-9 ↗